Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
29 Aug 2023
Historique:
received: 04 04 2023
accepted: 17 07 2023
medline: 31 8 2023
pubmed: 31 8 2023
entrez: 31 8 2023
Statut: aheadofprint

Résumé

To evaluate the retention rate, treatment response and safety of tocilizumab (TCZ) as first-line biologic treatment in rheumatoid arthritis (RA) patients with inadequate response to disease-modifying anti-rheumatic drugs (DMARD-IR). The TReasure Registry is a multicentre, web-based registry of RA and spondyloarthritis patients across Turkey. DMARD-IR RA patients who received TCZ as first-line biologic treatment were included in this registry for efficacy and safety. Demographic and clinical data, treatments, and adverse events were collected. Drug retention rate was estimated using Kaplan-Meier analysis. Among 642 RA patients who ever used TCZ, 258 DMARD-IR RA patients (male/female: 18.2%/81.8%, mean age, 54.41 years) received TCZ as first-line biologic. The median disease duration was 97 (range, 60-179) months and the median TCZ treatment duration was 15 (range, 6-28) months. At the 6th and 12th months of TCZ treatment, the decrease in disease activity scores from baseline was significant. The Kaplan-Meier analysis revealed the retention rate of TCZ at the 12th, 24th, 36th, and 60th months as 81.1%, 73.8%, 66.2%, and 63.6%, respectively. Fifty-seven (22%) patients discontinued TCZ; the main reason being primary or secondary inefficacy (n=29). Over 80% drug retention rate at 12th month of TCZ treatment in this real-world study was concordant with previously conducted TCZ clinical studies. Significant reductions not only in the disease activity score-28 but also in the simplified disease activity index (SDAI) and clinical disease activity index (CDAI) scores, along with health assessment questionnaire (HAQ) scores, supported the impact of TCZ in RA management with a good safety profile.

Identifiants

pubmed: 37650346
pii: 19697
doi: 10.55563/clinexprheumatol/2h6ma1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Omer Karadag (O)

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey. drokaradag@gmail.com.

Bayram Farisogullari (B)

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Burcu Yagiz (B)

Division of Rheumatology, Department of Internal Medicine, Bursa Uludag University Faculty of Medicine, Health Application and Research Center, Bursa, Turkey.

Abdulsamet Erden (A)

Clinic of Rheumatology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey.

Zeliha Ademoglu (Z)

Division of Rheumatology, Department of Internal Medicine, Trakya University Faculty of Medicine, Edirne, Turkey.

Gezmis Kimyon (G)

Division of Rheumatology, Department of Internal Medicine, Hatay Mustafa Kemal University Tayfur Ata Sokmen Faculty of Medicine, Hatay, Turkey.

Nazife Sule Bilge (NS)

Department of Rheumatology, Eskisehir Osmangazi University Health, Application and Research Hospital, Eskisehir, Turkey.

Ozan Cemal Icacan (OC)

Division of Rheumatology, Department of Internal Medicine, Istanbul Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

Levent Kilic (L)

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Belkis Nihan Coskun (BN)

Division of Rheumatology, Department of Internal Medicine, Bursa Uludag University Faculty of Medicine, Health Application and Research Center, Bursa, Turkey.

Emine Duygu Ersozlu (ED)

Department of Rheumatology, Adana City Training and Research Hospital, Adana, Turkey.

Orhan Kucuksahin (O)

Clinic of Rheumatology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey.

Ridvan Mercan (R)

Division of Rheumatology, Department of Internal Medicine, Tekirdag Namik Kemal University Faculty of Medicine, Tekirdag, Turkey.

Suleyman Serdar Koca (SS)

Division of Rheumatology, Department of Internal Medicine, Firat University Faculty of Medicine, Firat University Hospital, Elazig, Turkey.

Emel Gonullu (E)

Division of Rheumatology, Department of Internal Medicine, Sakarya University Faculty of Medicine, Sakarya, Turkey.

Muhammet Cinar (M)

Clinic of Rheumatology, University of Health Sciences Gulhane Training and Research Hospital, Ankara, Turkey.

Servet Akar (S)

Division of Rheumatology, Department of Internal Medicine, Izmir Katip Celebi University, Atatürk Education and Research Hospital, Izmir, Turkey.

Hakan Emmungil (H)

Division of Rheumatology, Department of Internal Medicine, Trakya University Faculty of Medicine, Edirne, Turkey.

Timucin Kasifoglu (T)

Department of Rheumatology, Eskisehir Osmangazi University Health, Application and Research Hospital, Eskisehir, Turkey.

Cemal Bes (C)

Division of Rheumatology, Department of Internal Medicine, Istanbul Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

Ahmet Omma (A)

Ankara Bilkent City Hospital, Rheumatology Clinic, Ankara, Turkey.

Yavuz Pehlivan (Y)

Division of Rheumatology, Department of Internal Medicine, Bursa Uludag University Faculty of Medicine, Health Application and Research Center, Bursa, Turkey.

Sedat Kiraz (S)

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Ihsan Ertenli (I)

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Ediz Dalkilic (E)

Division of Rheumatology, Department of Internal Medicine, Bursa Uludag University Faculty of Medicine, Health Application and Research Center, Bursa, Turkey.

Umut Kalyoncu (U)

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Classifications MeSH